stockportfolio.pro
Stocks / ARWR vs NUVL
ARWR vs NUVL
Arrowhead Pharmaceuticals, Inc. and Nuvalent, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Arrowhead Pharmaceuticals, Inc. (ARWR) | Nuvalent, Inc. (NUVL) | |
|---|---|---|
| Market cap | $10.0B | $9.8B |
| Revenue (latest FY) | $829.45M | $0 |
| Net income (latest FY) | $-1.63M | $-425.38M |
| Revenue growth (5y CAGR) | 56.6% | — |
| Net margin | -0.2% | — |
| Return on equity | -0.3% | -34.1% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ARWR — free Open NUVL — freeFrequently asked questions
Which is bigger, ARWR or NUVL?
Arrowhead Pharmaceuticals, Inc. is larger by market capitalization — $10.0B versus $9.8B.
Which grows faster, ARWR or NUVL?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.